79 related articles for article (PubMed ID: 3973471)
1. alpha 2-Plasmin inhibitor metabolism in patients with liver cirrhosis.
Knot EA; Drijfhout HR; ten Cate JW; de Jong E; Iburg AH; Kahlé LH; Grijm R
J Lab Clin Med; 1985 Mar; 105(3):353-8. PubMed ID: 3973471
[TBL] [Abstract][Full Text] [Related]
2. Alpha 2-antiplasmin: functional characterization and metabolism in a heterozygote deficient patient.
Knot EA; ten Cate JW; Lamping RJ; Gie LK
Thromb Haemost; 1986 Jun; 55(3):375-8. PubMed ID: 3750266
[TBL] [Abstract][Full Text] [Related]
3. Bradykinin in the ascitic fluid of patients with liver cirrhosis.
Cugno M; Salerno F; Nussberger J; Bottasso B; Lorenzano E; Agostoni A
Clin Sci (Lond); 2001 Dec; 101(6):651-7. PubMed ID: 11724653
[TBL] [Abstract][Full Text] [Related]
4. Catabolism of human fibrinogen fragment D in normal subjects and patients with liver cirrhosis.
Ardaillou N; Yvart J; Le Bras P; Larrieu MJ
Thromb Haemost; 1980 Dec; 44(3):146-9. PubMed ID: 7466742
[TBL] [Abstract][Full Text] [Related]
5. Clinical studies on alpha 2 plasmin inhibitor.
Roman S; Knauer O; Cucuianu M
Med Interne; 1990; 28(1):73-81. PubMed ID: 2126640
[TBL] [Abstract][Full Text] [Related]
6. Plasma antithrombin III, alpha 2-plasmin inhibitor and plasminogen activities in cases of various liver diseases.
Ito K; Niwa M; Kawada T; Tanaka Y
Tokai J Exp Clin Med; 1986 Nov; 11(5):345-52. PubMed ID: 3672563
[TBL] [Abstract][Full Text] [Related]
7. Antithrombin III: biodistribution in healthy volunteers.
Knot EA; de Jong E; ten Cate JW; Gie LK; van Royen EA
Thromb Haemost; 1987 Dec; 58(4):1008-11. PubMed ID: 3445222
[TBL] [Abstract][Full Text] [Related]
8. [Studies on the mechanism of hyperfibrinolysis in liver cirrhosis--changes of plasma t-PA, PAI-1 and active PAI-1 levels in liver cirrhosis].
Matsuura R; Soma M; Maeda Y; Kasakura S
Rinsho Byori; 1995 Dec; 43(12):1256-60. PubMed ID: 8569037
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of fibrinogen in cirrhosis of the liver.
Tytgat GN; Collen D; Verstraete M
J Clin Invest; 1971 Aug; 50(8):1690-701. PubMed ID: 5163179
[TBL] [Abstract][Full Text] [Related]
10. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC
Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147
[TBL] [Abstract][Full Text] [Related]
11. Colchicine clearance is impaired in alcoholic cirrhosis.
Leighton JA; Bay MK; Maldonado AL; Schenker S; Speeg KV
Hepatology; 1991 Dec; 14(6):1013-5. PubMed ID: 1959847
[TBL] [Abstract][Full Text] [Related]
12. [Clinical relevance of determination of plasma ATIII and alpha 2 PI activities in patients with DIC--application of the molecular markers for the analysis of pathophysiology of DIC].
Okajima K
Rinsho Byori; 1994 Jan; 42(1):45-55. PubMed ID: 8107283
[TBL] [Abstract][Full Text] [Related]
13. Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics.
Tietge UJ; Böker KH; Manns MP; Bahr MJ
Am J Physiol Endocrinol Metab; 2004 Jul; 287(1):E82-9. PubMed ID: 15010338
[TBL] [Abstract][Full Text] [Related]
14. Relative versus absolute carbohydrate-deficient transferrin as a marker of alcohol consumption in patients with acute alcoholic hepatitis.
Halm U; Tannapfel A; Mössner J; Berr F
Alcohol Clin Exp Res; 1999 Oct; 23(10):1614-8. PubMed ID: 10549992
[TBL] [Abstract][Full Text] [Related]
15. [Fibrinolysis in chronic liver diseases studied by in vitro blood coagulation tests].
Pósán E; Tornai I; Udvardy M
Orv Hetil; 1994 Dec; 135(51):2821-4. PubMed ID: 7838517
[TBL] [Abstract][Full Text] [Related]
16. Antithrombin III metabolism in patients with liver disease.
Knot E; Ten Cate JW; Drijfhout HR; Kahlé LH; Tytgat GN
J Clin Pathol; 1984 May; 37(5):523-30. PubMed ID: 6725600
[TBL] [Abstract][Full Text] [Related]
17. Kinetics of the inhibition of plasmin in acidified human plasma.
Lijnen HR; Maes M; Castel M; Samama M; Collen D
Thromb Haemost; 1982 Dec; 48(3):257-9. PubMed ID: 6219470
[TBL] [Abstract][Full Text] [Related]
18. Systemic nitric oxide production and renal function in nonazotemic human cirrhosis: a reappraisal.
Sansoè G; Silvano S; Mengozzi G; Smedile A; Todros L; Baronio M; Bonardi L; Rizzetto M
Am J Gastroenterol; 2002 Sep; 97(9):2383-90. PubMed ID: 12358261
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of fibrinolysis in poorly controlled, hospitalized type 2 diabetic patients by short-term metabolic control: association with a decrease in plasminogen activator inhibitor 1.
Aso Y; Okumura KI; Yoshida N; Tayama K; Takemura Y; Inukai T
Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):175-80. PubMed ID: 15127320
[TBL] [Abstract][Full Text] [Related]
20. Tyramine kinetics and metabolism in cirrhosis.
Faraj BA; Fulenwider JT; Rypins EB; Nordlinger B; Ivey GL; Jansen RD; Ali FM; Camp VM; Kutner M; Schmidt F; Rudman D
J Clin Invest; 1979 Aug; 64(2):413-20. PubMed ID: 457860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
